Opinion|Videos|November 19, 2026

ASCENT-03 and TROPION-Breast02: Comparing ADC Efficacy, Safety, and Treatment Considerations in Metastatic TNBC

In this segment, the expert panel discusses the clinical implications of ASCENT-03, evaluating sacituzumab govitecan (SG) against the findings from TROPION-Breast02, which investigated datopotamab deruxtecan (Dato-DXd) in first-line metastatic triple-negative breast cancer (TNBC).

In this segment, the expert panel discusses the clinical implications of ASCENT-03, evaluating sacituzumab govitecan (SG) against the findings from TROPION-Breast02, which investigated datopotamab deruxtecan (Dato-DXd) in first-line metastatic triple-negative breast cancer (TNBC). The experts consider differences in trial design, eligibility criteria, chemotherapy control arms, and subsequent treatment, including the high proportion of patients initially assigned to chemotherapy in ASCENT-03 who subsequently received SG. They discuss how crossover and subsequent therapies may complicate interpretation of overall survival findings and why cross-trial comparisons require caution. The panel also examines differences in administration schedules and toxicity profiles, including neutropenia and infection with SG, and stomatitis and ocular toxicity with Dato-DXd. Experts consider the clinical relevance of progression-free survival, overall survival, response rates, duration of response, and quality of life when selecting treatment. The discussion highlights the importance of balancing efficacy with treatment burden, including the practical challenges of managing adverse events, monitoring ocular toxicity, and maintaining patients’ daily activities. The panel concludes by emphasizing individualized treatment decisions that incorporate clinical evidence, toxicity management, patient preferences, and the goal of extending survival while preserving quality of life.


Related to this article